Fundraising Fox
Simcha Therapeutics
New Haven, US · Delaware LLC · 8 employees on LinkedIn · 10 known investors
Find your way into Simcha Therapeutics
Each arrow is one introduction. Sign up to fill in the first one.
230 people can intro you to Beatrice
Ask Anil S. Jina to introduce you to Beatrice McQueen
You →Anil · together at PPD →Beatrice
Sign up to find every way you can get introduced to Simcha Therapeutics
- Your email: who you already know at Simcha Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Simcha Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Simcha is a biotechnology company developing new cancer medicines based on immune biology research. It focuses on translating discoveries in immune biology into oncology drugs for patients with cancer.
Founders & leadership
BM
Beatrice McQueenChief Operating Officer (Life Science)Chief Operating Officer at Simcha Therapeutics, Beatrice McQueen holds a Ph.D. in Pharmacokinetics and Drug Metabolism from UC San Francisco and an EMBA from UCLA Anderson School of Management. She has extensive experience across pharmaceutical drug development, R&D, operations, and finance, with expertise spanning candidate selection, manufacturing, regulatory filings, and clinical program management.
SR
Sanuj RavindranChief Executive Officer
JB
Jeremy BartonChief Medical Director
HU
Hirdesh UppalSenior Vice President Translational Research and Development Sciences
JC
Joseph CatinoNamed on SEC filing
Board
YL
Yiming LiBoard director
JB
RS
Richard SollManager
AH
Axel HoosBoard director
TR
Terry RosenBoard director
Investors · 10
Connecticut Innovationslisted by Connecticut InnovationsNew Haven · $500K – $2M
How we know: Connecticut Innovations's portfolio page · funding news · Not right? Tell us
Pfizer Venture Investmentslisted by Pfizer Venture Investments$5M – $20M
How we know: Pfizer Venture Investments's portfolio page · Not right? Tell us
SR One Capital Managementlisted by SR One Capital ManagementRedwood City
How we know: SR One Capital Management's portfolio page · a partner's Signal profile · funding news · globenewswire.com · Not right? Tell us
Axial VCreportedSan Francisco · $100K – $5M
How we know: the VCSheet dataset · Not right? Tell us
Also in the syndicate · 3
ArrowMark PartnersLogos CapitalSR Onelead
Reported raises · per SEC filings
Form D private placements$68.1M disclosed across 4 rounds · 2018–2025
▶$7.1MraisedJun 2025 · 5 investors · BiotechnologyRule 506(b)
▶$7.1MraisedJun 2025 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Yiming LiDirector
- Axel HoosDirector
- Terry RosenDirector
- Aaron RingExecutive Officer, Director
- Jake BauerExecutive Officer, Director
- Beatrice McQueenExecutive Officer
- Sanuj RavindranExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $7.1M
- First sale
- Jun 2025
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$40MraisedSep 2021 · 14 investors · BiotechnologyRule 506(b)
▶$40MraisedSep 2021 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Simeon GeorgeDirector
- Terry L. RosenDirector
- Aaron RingExecutive Officer, Director
- Lennart H. LeeDirector
- Beatrice McQueenExecutive Officer
- Offering amount
- $40M
- Amount sold
- $40M
- First sale
- Aug 2021
- Incorporated
- Limited Liability Company, Delaware, 2018
- Federal exemptions
- 06b
▶$16.6MraisedMay 2020 · 14 investors · BiotechnologyRule 506(b)
▶$16.6MraisedMay 2020 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Aaron RingExecutive Officer, Director
- Terry L. RosenDirector
- Lennart H. LeeDirector
- Gu CuipingDirector
- Beatrice McQueenExecutive Officer
- Offering amount
- $25.6M
- Amount sold
- $16.6M
- First sale
- May 2020
- Incorporated
- Limited Liability Company, Delaware, 2018
- Federal exemptions
- 06b
▶$4.4MraisedJul 2018 · 9 investors · BiotechnologyRule 506(b)
▶$4.4MraisedJul 2018 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard SollDirector
- Terry RosenDirector
- Aaron RingExecutive Officer, Director
- Joseph CatinoExecutive Officer
- Offering amount
- $6M
- Amount sold
- $4.4M
- First sale
- Jul 2018
- Incorporated
- Limited Liability Company, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
SoluSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Fred HutchFred Hutch is a cancer research institute that develops biomarkers, therapies, and stem cell products for research and clinical use, and provides data infrastructure and funding to commercialize discoveries into treatments and spinout companies.
Shape TherapeuticsShapeTX develops programmable RNA medicines by combining artificial intelligence with RNA technology to address genetic causes of disease.
Companies working in the same space as Simcha Therapeutics.
In the news
Frequently asked questions
- What does Simcha Therapeutics do?
- Simcha is a biotechnology company developing new cancer medicines based on immune biology research. It focuses on translating discoveries in immune biology into oncology drugs for patients with cancer.
- Who founded Simcha Therapeutics?
- Simcha Therapeutics was founded by Aaron Ring.
- Who are Simcha Therapeutics's investors?
- Simcha Therapeutics's investors include Connecticut Innovations, Pfizer Venture Investments, SR One Capital Management, Axial VC, Biotechnology Value Fund, Rock Springs Capital, Samsara BioCapital.
- How much funding has Simcha Therapeutics raised?
- Simcha Therapeutics has disclosed $68.1M raised across 4 rounds.
- Where is Simcha Therapeutics headquartered?
- Simcha Therapeutics is headquartered in New Haven, US.